ANI Pharmaceuticals Inc represents values of innovation, integrity, and quality in the pharmaceutical industry. With a strong corporate philosophy centered around customer focus, ANI Pharmaceuticals consistently strives to provide effective and affordable solutions for patients. The company's commitment to excellence is reflected in their rigorous research and development process, ensuring the production of safe and reliable pharmaceutical products. With a focus on growth and expansion, ANI Pharmaceuticals continues to create value for their customers, shareholders, and employees through their dedication to continuous improvement and strategic partnerships.

ANI Pharmaceuticals Inc is primarily present in the United States.

ANI Pharmaceuticals Inc has achieved several significant milestones. In recent years, the company successfully acquired a portfolio of 23 generic drug products from Teva Pharmaceuticals, further expanding its product offerings. ANI Pharmaceuticals also obtained approval from the U.S. Food and Drug Administration (FDA) for several Abbreviated New Drug Applications (ANDAs), enabling the company to bring numerous generic products to market. Furthermore, ANI Pharmaceuticals has made substantial progress in developing a pipeline of complex generic and branded pharmaceutical products. These achievements demonstrate the company's dedication to growth, innovation, and providing high-quality medications to patients.

ANI Pharmaceuticals Inc. is a leading pharmaceutical company with a rich history and strong background. Founded in 2001, ANI specializes in developing, manufacturing, and marketing prescription and over-the-counter (OTC) pharmaceuticals. The company focuses primarily on complex products, including controlled substances and niche generics. ANI Pharmaceuticals has made significant strides in the industry, expanding its product portfolio through strategic acquisitions and partnerships. With a commitment to quality and innovation, ANI has established itself as a reliable provider of high-quality medications. The company continues to grow and diversify its offerings, ensuring a positive impact on the healthcare market.

The main competitors of ANI Pharmaceuticals Inc in the market are companies such as Teva Pharmaceutical Industries Ltd, Mylan N.V., and Endo International plc. These companies also operate in the pharmaceutical industry and offer a variety of products and services that may overlap with ANI Pharmaceuticals. However, ANI Pharmaceuticals differentiates itself through its focus on developing and commercializing niche branded pharmaceuticals. By continuously innovating and expanding its product portfolio, ANI Pharmaceuticals strives to maintain a competitive edge in the market.

ANI Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

ANI Pharmaceuticals Inc's business model revolves around the development, manufacturing, and marketing of specialty pharmaceutical products. As a specialty pharmaceutical company, ANI focuses on niche therapeutic areas such as cardiovascular, dermatology, and central nervous system disorders. By leveraging its strong research and development capabilities, ANI identifies opportunities in the market, develops new products or acquires existing ones, and then manufactures and markets them. This business model allows ANI Pharmaceuticals Inc to provide innovative and high-quality medications to patients while maintaining sustainable growth and profitability in the pharmaceutical industry.

ANI Pharmaceuticals의 P/E 비율은 8.75입니다.

ANI Pharmaceuticals의 P/S 비율은 1.4입니다.

ANI Pharmaceuticals에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 ANI Pharmaceuticals 매출은 734.51 백만 USD입니다.

예상되는 ANI Pharmaceuticals 이익은 117.21 백만 USD입니다.

ANI Pharmaceuticals Inc. is an American pharmaceutical company that is engaged in the development, manufacturing, and distribution of branded and generic drugs. The company is headquartered in Baudette, Minnesota and has a wide range of products in various sectors such as anti-infectives, cardiology, oncology, pain relief, and others. ANI Pharmaceuticals Inc. primarily focuses on the manufacturing of generics and offers a wide range of generic products, mainly distributed in the United States. They also offer contract manufacturing services for pharmaceutical products and have acquired licensing rights from other pharmaceutical companies. In addition, ANI Pharmaceuticals Inc. has a strong presence in the US market and continuously strives to expand its product portfolio and improve customer satisfaction.

ANI Pharmaceuticals은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

ANI Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

ANI Pharmaceuticals의 ISIN은 US00182C1036입니다.

ANI Pharmaceuticals의 WKN은 A1W15D입니다.

ANI Pharmaceuticals의 티커는 ANIP입니다.

지난 12개월 동안 ANI Pharmaceuticals은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 ANI Pharmaceuticals은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

ANI Pharmaceuticals의 현재 배당 수익률은 입니다.

ANI Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

ANI Pharmaceuticals은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

ANI Pharmaceuticals은 '건강' 섹터에 속합니다.

ANI Pharmaceuticals의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 ANI Pharmaceuticals는 0 USD를 배당금으로 지급했습니다.

ANI Pharmaceuticals의 배당금은 USD에 지급됩니다.